Yeast-Based Screens to Target Alpha-Synuclein Toxicity

Brás, Inês Caldeira; Popova, Blagovesta; Braus, Gerhard H.; Outeiro, Tiago F.

doi:10.1007/978-1-4939-9124-2_12

Cited by 4 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These works led to the identification of a large number of compounds with a different chemical nature that reduce the toxicity of alpha-synuclein; i.e., mannosylglycerate (Faria et al, 2013), Latrepirdine (Dimebon; dimebolin) (Steele et al, 2013), several cyclic peptides (Kritzer et al, 2009), cerium oxide nanoparticles (Ruotolo et al, 2020), flavonoids, (poly)phenols, plant catechins [for example, from the leaves of Arbutus unedo L. (strawberry tree) and (green tea; Griffioen et al, 2006;Williams et al, 2007;Macedo et al, 2018), and yeast red pigment (a polymer of 1-(5-phosphoribosyl)-5-aminoimidazole; Nevzglyadova et al, 2018)]. The methodology used in this type of research is rapidly developing, and the use of new screening systems for bioactive compounds in yeast (Brás et al, 2019) will allow the identification of new low-molecular-weight compounds-blockers of the formation of protein aggregates.…”

Section: Yeast Models: What Could Be Simpler?mentioning

confidence: 99%

Modeling Parkinson’s Disease: Not Only Rodents?

Шадрина

Slominsky

2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a common chronic progressive multifactorial neurodegenerative disease. In most cases, PD develops as a sporadic idiopathic disease. However, in 10%–15% of all patients, Mendelian inheritance of the disease is observed in an autosomal dominant or autosomal recessive manner. To date, mutations in seven genes have been convincingly confirmed as causative in typical familial forms of PD, i.e., SNCA, LRRK2, VPS35, PRKN, PINK1, GBA, and DJ-1. Family and genome-wide association studies have also identified a number of candidate disease genes and a common genetic variability at 90 loci has been linked to risk for PD. The analysis of the biological function of both proven and candidate genes made it possible to conclude that mitochondrial dysfunction, lysosomal dysfunction, impaired exosomal transport, and immunological processes can play important roles in the development of the pathological process of PD. The mechanisms of initiation of the pathological process and its earliest stages remain unclear. The study of the early stages of the disease (before the first motor symptoms appear) is extremely complicated by the long preclinical period. In addition, at present, the possibility of performing complex biochemical and molecular biological studies familial forms of PD is limited. However, in this case, the analysis of the state of the central nervous system can only be assessed by indirect signs, such as the level of metabolites in the cerebrospinal fluid, peripheral blood, and other biological fluids. One of the potential solutions to this problem is the analysis of disease models, in which it is possible to conduct a detailed in-depth study of all aspects of the pathological process, starting from its earliest stages. Many modeling options are available currently. An analysis of studies published in the 2000s suggests that toxic models in rodents are used in the vast majority of cases. However, interesting and important data for understanding the pathogenesis of PD can be obtained from other in vivo models. Within the framework of this review, we will consider various models of PD that were created using various living organisms, from unicellular yeast (Saccharomyces cerevisiae) and invertebrate (Nematode and Drosophila) forms to various mammalian species.

show abstract